Phentermine and Topirimate for Type 2 Diabetes Patients

Posted: February 13, 2015 at 9:05 am

In two randomized, double-blind and placebo-controlled studies, the safety and efficacy of treatment with phentermine (PHEN) and topiramate ER (TPM ER) (Qsymia) plus lifestyle for weight loss and glycemic benefits were measured. The studies included obese/overweight adults with type 2 diabetes. In the OB-202 study, subjects were randomized at a 1:1 ratio to receive placebo…

Best weight reduction pills and safe methods to apply it

Posted: January 29, 2015 at 11:50 am

Have you ever consideration to buy weight loss pills for losing weight fast or engaging in shape. I can state that most people can readily admit they may have, at once or two inside their lives. One can sense this with all the growing niche for these pills. Not to be blown away that certain…

DR. OZ Diet Pills Retracted

Posted: November 5, 2014 at 11:17 am

Dr. Mehmet Oz has been under fire recently for promoting weight loss products on TV’s “The Dr. Oz Show” that aren’t backed by a lot of scientific evidence. Now a study supporting one of those products, diet pills made with green coffee bean extract, has been withdrawn by its lead researchers. “The sponsors of the…

Arena Pharmaceuticals Holds Back Data

Posted: October 30, 2014 at 12:46 pm

Arena Pharmaceuticals (ARNA) provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination. Key heart safety and efficacy data were not disclosed in the company’s press release announcing results from a short, proof-of-concept study. Obese patients offered the “Bel-phen” combo for 12 weeks did not report higher rates of headache, dizziness, nausea, fatigue,…

Are obesity drugs nearing a breakout?

Posted: October 9, 2014 at 10:11 am

Analysts have been waiting–and waiting–for drugmakers to realize the growth they’ve predicted for the obesity market. And with a couple of pharma companies preparing to pony up R&D and marketing resources for their obesity products, it could finally be on the way. Novo Nordisk ($NVO)–whose weight-loss injection Saxenda won the favor of an FDA advisory…

New Diet Pills Not Doing So Good

Posted: May 17, 2014 at 2:36 am

Based on a survey of MedPage Today readers the recently approved diet pills Qsymia and Belviq haven’t been prescribed by doctors as much as predicted. Among nearly 1,000 responses from doctors, only 6.4% said they prescribed Qsymia (phentermine/topiramate) simply 3.3% wrote for Belviq (lorcaserin) — although survey, conducted jointly by MedPage Today, Everyday Health, and…

The Significance Of Weight Loss

Posted: April 26, 2014 at 4:14 am

When it comes to weight-loss, everybody wants to know what the most efficient technique is. How could they not? More than half of most adults in America are overweight and are also at risk for heart related illnesses. An estimated 300,000 deaths 12 months are related to diabetes, stroke, and heart problems. This statistic is…

Problems with Rapid Weight Loss

Posted: April 9, 2014 at 12:22 pm

Most fat reduction products and services currently available on the market promise quick, easy fat reduction. They emphasize decrease in a specific variety of pounds spanning a short period of time. This can be a really appealing possibility, particularly if you’re seeking to drop some weight as a way to fit into a relationship dress,…

The Two New Diet Pills Not The Solution

Posted: February 20, 2014 at 1:18 pm

The two most recently introduced new agents for weight loss in the United States, lorcaserin ( Belviq, Eisai) and phentermine-topiramate ( Qysmia, Vivus), represent “slim pickings” for the treatment of obesity based on the available evidence to date, say two doctors. They are particularly concerned about cardiovascular and psychiatric/neurologic side effects with the drugs. Writing…

Phentermine/Topiramate Reduces Type 2 Diabetes

Posted: November 12, 2013 at 11:00 am

Treatment with a weight-loss drug appeared to help pre-diabetic and diabetic patients shed pounds and improve dysglycemia, researchers said here. After 56 weeks of treatment with extended-release phentermine/topiramate (Qsymia), obese/overweight individuals, with and without diagnosed type 2 diabetes, experienced a mean percent weight loss ranging from 6.8% to 8.9% with a low-dose regimen, and 8.8%…

Copyright © 2005-2011 PhenForum.com. All rights reserved. Privacy policy | Terms Of use | Contact Us